Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

North Branch Land Trust invites nature-lovers, conservationists and families to attend our Paddle and Pour event. From 11 a.m. to 1 p.m. Saturday, June 21, participants will have an introductory ...

Martini started helping people in 2004 after Hurricane Charley hit Florida. But more than 20 years later, what began as ...

May was a terrible month for biotech, but June is (early days) looking better.

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

Stocks closed higher on Tuesday as the Nasdaq Composite finished the day higher for the year even as uncertainty over global ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Merck recently made a nonbinding offer to acquire Swiss biotech firm MoonLake for over $3 billion, seeking to boost its drug ...

Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.63M to 6.10M. This put 21.56% of the company's publicly available shares short.